T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

Status Active, not recruiting

Clinical Trial Summary

This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT). This study is designed to see whether an investigational cellular product of immune cells obtained from a donor's cells that have been treated so that the type of cells that can lead to graft vs host disease have been removed can be safely administered. These cell products are administered following the initial stem cell transplant to assess the effect and improvement on minimal residual disease status, infectious complication, progression-free and overall survival.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Leukemia, Lymphoid
Myeloid Malignancy
Neoplasms
Neoplasms, Plasma Cell
Plasmacytoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT05350163
Study type	Interventional
Source	Baptist Health South Florida
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	April 5, 2022
Completion date	April 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04501120` - Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML	Phase 1/Phase 2
Not yet recruiting	`NCT06090513` - Molecular Services and EMR-Lab Integration Application (ELIA) for Reducing Healthcare Disparities in Cancer Patients
Recruiting	`NCT05579769` - A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies	Phase 2
Recruiting	`NCT05583175` - Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies	Phase 2
Terminated	`NCT01596699` - Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation	Phase 2
Recruiting	`NCT04906031` - Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations	Phase 2
Recruiting	`NCT05455294` - Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms	Phase 1
Recruiting	`NCT03850418` - Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant	Phase 2
Recruiting	`NCT02958462` - Pre-myeloid Cancer and Bone Marrow Failure Clinic Study	N/A
Recruiting	`NCT03855371` - Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS	Phase 1
Recruiting	`NCT05841771` - Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.	Phase 2
Completed	`NCT04214860` - APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies	Phase 1
Not yet recruiting	`NCT06378437` - A Study of GLB-001 in Patients With Myeloid Malignancies	Phase 1
Not yet recruiting	`NCT05875805` - A Telehealth Advance Care Planning Intervention	N/A
Not yet recruiting	`NCT06129734` - Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant	Phase 1/Phase 2